Creegan & Nassoura Financial Group’s Novartis NVS Stock Holding History

Creegan & Nassoura Financial Group’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$1.56M	Hold	11,325	–	–	1.01%	36
2025 Q3	$1.45M	Hold	11,325	–	–	0.94%	40
2025 Q2	$1.37M	Hold	11,325	–	–	0.89%	40
2025 Q1	$1.26M	Sell	11,325 -75	-0.7%	-$7.98K	0.84%	42
2024 Q4	$1.11M	Sell	11,400 -250	-2%	-$26.7K	0.75%	46
2024 Q3	$1.34M	Sell	11,650 -150	-1%	-$17K	0.84%	43
2024 Q2	$1.26M	Sell	11,800 -200	-2%	-$20.1K	0.86%	42
2024 Q1	$1.16M	Hold	12,000	–	–	0.78%	46
2023 Q4	$1.21M	Hold	12,000	–	–	0.88%	42
2023 Q3	$1.22M	Hold	12,000	–	–	0.95%	43
2023 Q2	$1.21M	Sell	12,000 -650	-5%	-$65K	0.89%	46
2023 Q1	$1.16M	Hold	12,650	–	–	0.89%	42
2022 Q4	$1.15M	Sell	12,650 -1,225	-9%	-$103K	0.89%	43
2022 Q3	$1.05M	Hold	13,875	–	–	0.91%	41
2022 Q2	$1.17M	Sell	13,875 -875	-6%	-$76.8K	0.99%	43
2022 Q1	$1.29M	Sell	14,750 -5,675	-28%	-$491K	0.97%	45
2021 Q4	$1.79M	Hold	20,425	–	–	1.35%	32
2021 Q3	$1.67M	Sell	20,425 -225	-1%	-$20.2K	1.42%	28
2021 Q2	$1.88M	Sell	20,650 -675	-3%	-$60.1K	1.61%	25
2021 Q1	$1.82M	Sell	21,325 -900	-4%	-$80.8K	1.63%	26
2020 Q4	$2.1M	Hold	22,225	–	–	2.02%	18
2020 Q3	$1.93M	Hold	22,225	–	–	2.08%	16
2020 Q2	$1.94M	Sell	22,225 -50	-0.2%	-$4.32K	2.19%	15
2020 Q1	$1.84M	Hold	22,275	–	–	2.4%	11
2019 Q4	$2.11M	Buy	+22,275	New	+$2M	2.12%	16
2016 Q3	$2.06M	Sell	29,183 -112	-0.4%	-$8.16K	2.41%	11
2016 Q2	$2.17M	Sell	29,295 -670	-2%	-$46.3K	2.56%	9
2016 Q1	$1.95M	Sell	29,965 -418	-1%	-$28.4K	2.3%	11
2015 Q4	$2.34M	Sell	30,383 -112	-0.4%	-$8.9K	2.66%	7
2015 Q3	$2.51M	Sell	30,495 -111	-0.4%	-$9.88K	2.86%	4
2015 Q2	$2.7M	Hold	30,606	–	–	2.81%	3
2015 Q1	$2.7M	Sell	30,606 -670	-2%	-$59.4K	2.78%	2
2014 Q4	$2.6M	Buy	+31,276	New	+$2.59M	2.65%	5

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Creegan & Nassoura Financial Group's NVS Position: Q4 2025 in Review

Creegan & Nassoura Financial Group held its Novartis (NVS) position steady in Q4 2025 at 11,325 shares worth $1.56M. The position accounts for 1.01% of the portfolio, ranked #36.

Creegan & Nassoura Financial Group first reported a position in NVS in Q4 2014 and has held it in 33 quarters since. The position peaked at $2.7M in Q1 2015. 1,509 funds tracked by Wall St. Rank hold NVS as of Q4 2025.

Creegan & Nassoura Financial Group held 11,325 shares of Novartis worth $1.56M as of Q4 2025.
Creegan & Nassoura Financial Group left its Novartis share count unchanged in Q4 2025.
Novartis made up 1.01% of Creegan & Nassoura Financial Group's portfolio in Q4 2025, its #36 holding.
Creegan & Nassoura Financial Group first reported a position in Novartis in Q4 2014 and has held it in 33 quarters since.
Creegan & Nassoura Financial Group's Novartis position peaked at $2.7M in Q1 2015.
1,509 funds tracked by Wall St. Rank held Novartis as of Q4 2025.

Based on Creegan & Nassoura Financial Group's 13F filing for Q4 2025, filed 17 Feb 2026.